Shaun R. Bagai
Shaun R. Bagai
Chief Executive Officer
Mr. Bagai brings over 21 years of medical technology expertise with a proven track record in leadership roles in clinical research, physician training, sales, marketing, and market development. He has successfully launched novel technologies into regional and global marketplaces in large corporations as well as growth-phase companies. He was instrumental in developing the European market for renal denervation for the treatment of hypertension which led to the acquisition of the first renal denervation company, Ardian, Inc., by Medtronic in 2011 for over $850M. Prior to joining RenovoRx, Mr. Bagai led global market development for HeartFlow, Inc., which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader development to create value resulting in the creation of HeartFlow-Japan. Prior to leaving HeartFlow, he also successfully orchestrated their largest clinical trial and contracted HeartFlow’s first global customers. Mr. Bagai is a graduate from the University of California, Santa Barbara with a B. Sc. in Biology/Pre-med.
Ramtin Agah, MD
Ramtin Agah, MD
Chief Medical Officer, Founder
Dr. Agah is currently Interventional Cardiologist at El Camino Hospital, Mountain View. He was previously Assistant Professor of Internal Medicine with the Division of Cardiology, University of Utah. Dr. Agah completed a Fellowship in Interventional Cardiology with Cleveland Clinic Foundation, a Residency in Internal Medicine with Baylor College of Medicine, Houston, Texas, and a Fellowship in Cardiology with U.C.S.F. in San Francisco, CA. He is a MD graduate of University of Texas Southwestern Medical School. Dr. Agah is a founder and the originator of the RenovoRx technology.
Chief Financial Officer
Since December 2020, Mr. Lehman has been affiliated with LS Associates, Inc. which provides on-demand C-level executives. Pursuant to the contract between LS Associates, Inc. and RenovoRx, Mr. Lehman became Chief Financial Officer upon completion of the initial public offering. From December 2019 to August 2020, Mr. Lehman was Chief Financial Officer of Avellino Lab USA, Inc., a precision medicine company. From October 2017 to February 2019, he was affiliated with Eureka Therapeutics, Inc., an immuno-oncology company, as Vice President, Finance from 2017 to 2018 and Chief Financial Officer from 2018 to 2019. From October 2013 to June 2017, Mr. Lehman was Vice President, Financial Strategy of Coherus Biosciences, Inc., a global biosimilars and immuno-oncology company. For over 25 years, Mr. Lehman has worked with venture-backed private and public industry leaders in areas of therapeutics, biosimilars, diagnostics, contract research and industrial biotechnology. He has experience in leveraging his broad industry network with investment banks, venture capital, and strategic pharmaceutical partners to raise dilutive and non-dilutive capital and has experience with investors and strategic partners in the United States, Europe, and Asia.
Vice President of Finance
Mr. Manners has a successful career as a finance executive in the Life Sciences Industry, including Pharma, Biotech, Medical Devices and Diagnostics. His significant contributions have occurred in a range of business environments, from early stage companies to global fortune 100 corporations, including J&J and Novartis. He received an MBA from Rider University and a BBA from Northeastern University.
Vice President of Operations
Mr. Paraschac brings 30 years of product development, operations and leadership experience in the medical technology industry to RenovoRx. His experience ranges from technology creation management in early-stage companies to product development and manufacturing transfer management during large-scale commercialization. He has experience in developing products in a diverse group of specializations including laparoscopic surgery, ophthalmology, ENT, coronary stenting, and structural heart. Prior to RenovoRx, Mr. Paraschac led the engineering team developing and transferring the Perclose AT to full scale commercial launch (acquired by Abbot Laboratories and currently marketed as the ProGlide) for which he was awarded the Abbot Laboratories Hospital Products Division President’s Award. He went on to lead the product development and roadmap strategy and manage an offsite production facility at Arstasis, developed contract manufacturers at Zelegent, and managed the transfer and CE mark activities on the Elixir DESyne X2 stent. He recently acted as R&D Fellow at Elixir medical expanding product development systems and capabilities. Mr. Paraschac holds a master’s degree in Mechanical Engineering from Worcester Polytechnic Institute.
Sr. Director, Clinical Operations and Research
Ms. Lama comes to RenovoRx with over 20 years of experience in pharmaceutical and medical device clinical research, on both the institution and sponsor sides. She has a strong domestic and global clinical operations leadership and project management experience in early and late phase clinical trials in a wide spectrum of disease indications. She led the implementation and management of research operations of an NCI-Designated Comprehensive Cancer Center at UCSF. Ms. Lama holds a BS degree in Microbiology and Chemistry and MS in Nutrition.
Imtiaz Qureshi, MD
Imtiaz Qureshi, MD
Director of Imaging
Dr. Qureshi went to the prestigious Aga Khan University School of Medicine and graduated with honors. He completed a post-doctoral Fellowship in Molecular Biology and Physiology at Yale University. He completed an internship at Yale School of Medicine in General Surgery and subsequently joined Hartford Hospital for Diagnostic Radiology Residency. He was the Chief Resident during his Residency. Subsequently, he went to Stanford University where he completed a Fellowship in Neuroradiology. He is currently at El Camino Hospital where he has been the Medical Director and Chief of Radiology for the last 10 years.
Dr. Qureshi’s research interests include Artificial Intelligence and Machine Learning in Imaging. He serves as an adviser to several keys companies developing new imaging platforms for Breast Imaging, Neuroimaging and Oncologic Imaging using Artificial Intelligence.